{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:21:58Z","timestamp":1790803318837,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jacl.2023.09.006","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T21:03:08Z","timestamp":1695243788000},"page":"563-566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A deeper dive into the REPRIEVE trial and the potential role of inflammation in residual risk"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5254-4067","authenticated-orcid":false,"given":"Dinesh K.","family":"Kalra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jacl.2023.09.006_bib0001","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1161\/CIR.0000000000000695","article-title":"Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: a Scientific Statement From the American Heart Association","volume":"140","author":"Feinstein","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacl.2023.09.006_bib0002","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jacc.2023.04.050","article-title":"Dyslipidemia in Human Immunodeficiency Virus Disease: JACC Review Topic of the Week","volume":"82","author":"Kalra","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2023.09.006_bib0003","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2352-3018(14)00032-0","article-title":"Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Lo","year":"2015","journal-title":"Lancet HIV"},{"issue":"12","key":"10.1016\/j.jacl.2023.09.006_bib0004","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1086\/652749","article-title":"Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection","volume":"201","author":"Neuhaus","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jacl.2023.09.006_bib0005","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: a Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","author":"Grundy","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.jacl.2023.09.006_bib0006","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jacl.2023.09.006_bib0007","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to Prevent Cardiovascular Disease in HIV Infection","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jacl.2023.09.006_bib0008","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1161\/CIRCULATIONAHA.117.028975","article-title":"Cardiovascular Risk Prediction Functions Underestimate Risk in HIV Infection","volume":"137","author":"Triant","year":"2018","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.jacl.2023.09.006_bib0009","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.2015.15629","article-title":"Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force","volume":"316","author":"Chou","year":"2016","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.jacl.2023.09.006_bib0010","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.amjcard.2015.03.025","article-title":"A Systematic Review of the Usefulness of Statin Therapy in HIV-Infected Patients","volume":"115","author":"Feinstein","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2023.09.006_bib0011","doi-asserted-by":"crossref","first-page":"18121","DOI":"10.1038\/s41598-022-23102-2","article-title":"Effectiveness and safety of statins on outcomes in patients with HIV infection: a systematic review and meta-analysis","volume":"12","author":"Vigny","year":"2022","journal-title":"Sci Rep"},{"issue":"19","key":"10.1016\/j.jacl.2023.09.006_bib0012","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1161\/CIRCULATIONAHA.117.032615","article-title":"High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD) a randomized superiority trial","volume":"137","author":"Taguchi","year":"2018","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacl.2023.09.006_bib0013","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jcmg.2017.07.011","article-title":"Effect of Early Pitavastatin Therapy on Coronary Fibrous-Cap Thickness Assessed by Optical Coherence Tomography in Patients With Acute Coronary Syndrome: the ESCORT Study","volume":"11","author":"Nishiguchi","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"10.1016\/j.jacl.2023.09.006_bib0014","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/QAD.0000000000001427","article-title":"Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV","volume":"31","author":"Toribio","year":"2017","journal-title":"AIDS"},{"issue":"14","key":"10.1016\/j.jacl.2023.09.006_bib0015","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1097\/QAD.0000000000001167","article-title":"Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection","volume":"30","author":"Longenecker","year":"2016","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.jacl.2023.09.006_bib0016","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/QAD.0000000000003175","article-title":"Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period","volume":"36","author":"Boccara","year":"2022","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.jacl.2023.09.006_bib0017","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/23744235.2021.1982140","article-title":"Effectiveness of ezetimibe in human immunodeficiency virus patients treated for hyperlipidaemia: a systematic review and meta-analysis","volume":"54","author":"Nirmala","year":"2022","journal-title":"Infect Dis (Lond)"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287423002684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287423002684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:39:29Z","timestamp":1761831569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287423002684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1933287423002684"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2023.09.006","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A deeper dive into the REPRIEVE trial and the potential role of inflammation in residual risk","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2023.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 National Lipid Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}